Cluster headache not responsive to sumatriptan: A retrospective study
| Autor: | Alberto Proietti Cecchini, Luca Giani, Giuseppe Lauria, Alberto Astengo, Massimo Leone |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Drug Agonist Time Factors medicine.drug_class media_common.quotation_subject Pain Cluster Headache Calcitonin gene-related peptide 03 medical and health sciences 0302 clinical medicine Humans Medicine 030212 general & internal medicine Retrospective Studies media_common Sumatriptan business.industry Cluster headache Retrospective cohort study General Medicine Middle Aged medicine.disease Anesthesia Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cephalalgia. 41:117-121 |
| ISSN: | 1468-2982 0333-1024 |
| Popis: | Introduction Subcutaneous sumatriptan, a 5HT1B/1D agonist, is the most effective drug in cluster headache acute treatment. About 25% of the patients do not respond to subcutaneous sumatriptan; the reasons for this are unknown. In this study, we compare clinical characteristics of cluster headache patients responding and non-responding to subcutaneous sumatriptan. Methods We retrospectively investigated the clinical records of 277 cluster headache patients. Patients reporting repeated satisfactory response to subcutaneous sumatriptan within 15 minutes were considered responders. Results Of 206 cluster headache patients who had used subcutaneous sumatriptan (mean age 45.6, 16% females, 48% chronic), 91% were responders, and 9% non-responders. Compared to responders, non-responders had longer and more frequent attacks: 60 (median; IQR 38–90) vs. 100 (60–120) minutes ( p = 0.028), 4 (2.5–5) vs. 3 (2–4) attacks/day ( p = 0.024). No other difference was found. Conclusions In cluster headache attacks with long duration and high frequency, pain mechanisms not involving 5HT1B/1D receptors may play a more relevant role. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|